Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Subject- and Investigator-blinded, Placebo-controlled, Paralleldesign, Bronchoprovocation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of Inhaled CSJ117 in Adult Subjects With Mild Atopic Asthma

Next Previous
Trial Profile

A Randomized, Subject- and Investigator-blinded, Placebo-controlled, Paralleldesign, Bronchoprovocation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of Inhaled CSJ117 in Adult Subjects With Mild Atopic Asthma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jun 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ecleralimab (Primary)
  • Indications Allergic asthma
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals

Most Recent Events

  • 19 May 2021 Results of an analysis assessing the molecular effects of bronchoprovocation and TSLP blockade in target tissue presented at the 117th International Conference of the American Thoracic Society
  • 20 May 2020 Primary endpoint (Late asthmatic response as measured by the maximum percentage decrease in FEV1) has been met presented at the 116th International Conference of the American Thoracic Society
  • 20 May 2020 Primary endpoint (Late asthmatic response as measured by the AUC for time adjusted percent decrease in FEV1) has been met presented at the 116th International Conference of the American Thoracic Society

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top